Nanox to Announce Fourth Quarter and Full Year 2020 Financial and Operating Results on Tuesday, March 2, 2021
NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q4 and full year 2020 financial results on March 2, 2021, prior to market opening. A conference call and webcast will follow at 8:30 AM ET. The company focuses on developing an innovative digital X-ray source for medical imaging, aiming to reduce costs and improve access to imaging services. The management's forward-looking statements highlight anticipated risks such as regulatory compliance, technological feasibility, and potential disruptions from public health issues.
- Preparing to release Q4 and full year 2020 financial results.
- Innovative technology aimed at reducing medical imaging costs.
- Plans for collaborations with leading healthcare organizations.
- Risks related to business interruptions from COVID-19.
- Uncertainties around regulatory clearance and compliance.
- Market acceptance of the proposed pay-per-scan model is uncertain.
Management to host conference call and webcast at 8:30 AM ET
NEVE ILAN, Israel, Feb. 17, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its fourth quarter and full year 2020 financial and operating results for the period ended December 31, 2020 on Tuesday, March 2, 2021 prior to the start of trading. Management will host a conference call and webcast at 8:30am ET on that day.
Conference call and webcast details
Tuesday, March 2, 2021 @ 8:30am ET
Investor domestic dial-in: 877-407-0789
Investor international dial-in: 201-689-8562
Conference ID: 13715494
Webcast link: http://public.viavid.com/index.php?id=143172
About Nanox:
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.
Forward-Looking Statements:
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; and Nanox's ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.
Contact:
Itzhak Maayan
Nanox Imaging
IR@nanox.vision
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com
FAQ
What is the date for NANO-X IMAGING's financial results announcement?
What time is the NANO-X IMAGING conference call?
What is the purpose of the conference call on March 2, 2021?
What challenges does NANO-X IMAGING face according to the press release?
